Innovent Biopharmaceutical Transformation
Full Speed for Global Development of Global assets
With established global development platform and rich experience, Innovent is accelerating to bring more
assets to global clinical trials in the near future.
Increasing Global Rights and
Global Potential Novel Molecules
A dozen of global potential assets in clinics
IBI188
(CD47)
IBI110
(LAG-3)
IBI939
(TIGIT)
IBI395
(PD1/IL2/IL21)
IBI324
(VEGF/ANG-2)
IBI322
(PD-L1/CD47)
IBI323
(PD-L1/LAG-3)
IBI302
(VEGF/C3)
IBI351
(KRAS G12C)
IBI333
(VEGF-A/VEGF-C)
IBI345
(Claudin 18.2 CAR-T)
IBI363
(PD-1/IL2)
4 PoC clusters
With global and blockbuster potential
•
IBI188 (CD47)
IBI188 positive POC data
readout in 1Q, 2022
IBI322 (PD-L1/CD47)
•
IBI110 (LAG-3)
IBI323 (PD-L1/LAG-3)
IBI939 (TIGIT)
IBI321 (PD-1/TIGIT)
IBI302 (VEGF/C3)
IBI324 (VEGF/ANG-2)
IBI333 (VEGF-A/VEGF-C)
•
IBI322 POC data readout in
2H,2022
IBI110 POC data readout in
1H, 2022
IBI323 phase 1a dose
escalation ongoing
IB1939 POC data readout in
2H, 2022
IBI321 phase 1a dose
escalation ongoing
IBI302 Phase 1b POC data
readout in 2H, 2021
IBI324 and IBI333 FPD in
2022
Enhanced global development
platform
•
Capable to conduct more global MRCTs
China Product
Development
(n=800+)
8 IND already approved
Global Clinical
Development
(n=150)
Seamless collaboration between China team and global
team, improved efficiency and synergy
Established team and expertise in the whole process
from IND to BLA
Innovent
Confidential
Copyright©2022 Innovent
19View entire presentation